Lei Yan

• Lead comprehensive product lifecycle management for flagship products including Lipitor, Norvasc, Viagra, Dymista, Zoloft, Celebrex, and Lyrica, leveraging RWE to bridge critical knowledge gaps and enhance market competitiveness • Spearhead preparation of Health Technology Assessment (HTA) dossiers for Zoloft and Celebrex, resulting in their inclusion in essential drug lists, and prepared health economics documentation for Dymista prior to market launch • Conduct comprehensive research on Value-Based Purchasing (VBP), Uniform Reimbursement Policy (URP), and private hospital regulations to inform strategic decisions and enhance market positioning • Lead the "Guardian Online" project integrating digital blood pressure monitors with hypertension patient management, developing a collaborative ecosystem across healthcare providers, caregivers, patients, and digital platforms • Design and develop innovative digital therapeutic solutions, leveraging technology to enhance patient engagement and care delivery while supporting product differentiation in competitive markets • Establish strategic partnerships with internal teams and external stakeholders to align business needs with market access strategies, driving impactful initiatives supporting both patient outcomes and organizational goals

• Contributed to product lifecycle management across all therapeutic areas • Engaged top-level key opinion leaders in various medical fields • Coached team members in scientific writing and real-world evidence generation • Navigated challenging and rapidly evolving market conditions

• Evaluated data quality and usability of official big data platforms in Ningbo Yinzhou, Fuzhou, Tianjin, and Chengdu, identifying optimal data sources for real-world studies • Contributed to the revision of Sichuan Provincial Health Commission medical big data usage guidelines, helping set industry standards • Conducted impactful real-world evidence studies for key products including Concor, Metformin, Stilamin, Cetrorelix, and Erbitux, with findings published in peer-reviewed journals and presented at high-profile conferences • Assessed usability and feasibility of datasets from leading domestic and international data companies, enabling selection of high-quality data sources for different therapeutic area products • Collaborated with KOLs and top academic institutions to address unmet medical needs and identify knowledge gaps in clinical practice across China

• Contributed to development of multiple products across various stages including Bridion, Isentress, Zerbaxa, Gardasil4, and Cetrotide • Supported Zepatier from Phase I through market launch, initiating RWE studies to accelerate clinical trials for multiple products • Authored epidemiology sections of product filing documents for China FDA regulatory submissions • Led real-world evidence studies to address regulatory queries and support product positioning • Reinforced company products as market leaders in specific therapeutic areas through strategic RWE studies • Facilitated engagement with influential key opinion leaders to address unmet medical needs in China • Contributed to new product launches by developing integrated marketing plans and guiding sales teams

• Led national-level epidemic control operations, including 2009-2010 avian influenza and hand-foot-mouth disease outbreaks • Conducted multiple field investigations of disease outbreaks of unknown etiology under direct assignment from the Ministry of Health and CDC headquarters • Contributed to national viral disease prevention guidelines and scientific foundations for infectious disease control policies • Led disease surveillance and control efforts following the Wenchuan earthquake, major floods, and other natural disasters • Established innovative applications of geographic information systems and satellite remote sensing in disease monitoring

• Participated in national disease control and health emergency policy development, providing expert responses to National People's Congress inquiries • Served as a national-level epidemiology expert leading disease prevention and control efforts for all major national events from 2009-2010 • Participated as team member and team leader in disease prevention and control following multiple major natural disasters including earthquakes, floods, and mudslides • Assisted in establishing the National Health Emergency Response Team, enhancing nationwide capacity for public health emergency response • Contributed to new drug and vaccine development strategies and implementation

• Practiced clinical medicine with focus on diagnostic radiology at one of China's premier academic medical centers • Member of the first cohort of physicians to obtain medical licensure under China's national licensing system

Advisor: Academician Li Xiaowen ("Barefoot Academician"), Co-advisor: Military Medical Science Academy Institute of Microbial Epidemiology